Literature DB >> 25907904

CCMCL1: a new model of aggressive mantle cell lymphoma.

Xiaoxian Zhao1, Selina Chen-Kiang2, Shashirekha Shetty1, Maurizio Di Liberto2, Juraj Bodo1, Lisa Durkin1, Ken Eng3, Olivier Elemento3, Mitchell R Smith4, Eric D Hsi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25907904      PMCID： PMC4432548          DOI： 10.1182/blood-2015-01-622795

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma.

Authors:  Alberto Zamò; German Ott; Tiemo Katzenberger; Patrick Adam; Claudia Parolini; Aldo Scarpa; Maurizio Lestani; Fabio Menestrina; Marco Chilosi
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

Review 2.  Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features.

Authors:  Suyang Hao; Warren Sanger; Mihaela Onciu; Raymond Lai; Ellen J Schlette; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2002-12       Impact factor: 7.842

3.  Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.

Authors:  Xiaoxian Zhao; Juraj Bodo; Danyu Sun; Lisa Durkin; Jeffrey Lin; Mitchell R Smith; Eric D Hsi
Journal:  Br J Haematol       Date:  2014-10-04       Impact factor: 6.998

4.  Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection.

Authors:  Laura K Fogli; Michael E Williams; Joseph M Connors; Yvonne Reid; Kathleen Brown; Owen A O'Connor
Journal:  Leuk Lymphoma       Date:  2015-02-11

Review 5.  Therapies for mantle cell lymphoma: current challenges and a brighter future.

Authors:  Alan P Skarbnik; Mitchell R Smith
Journal:  Discov Med       Date:  2013-03       Impact factor: 2.970

6.  Establishment and characterization of a new mantle cell lymphoma cell line, Mino.

Authors:  R Lai; T J McDonnell; S L O'Connor; L J Medeiros; R Oudat; M Keating; M B Morgan; T J Curiel; R J Ford
Journal:  Leuk Res       Date:  2002-09       Impact factor: 3.156

7.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Authors:  David Chiron; Maurizio Di Liberto; Peter Martin; Xiangao Huang; Jeff Sharman; Pedro Blecua; Susan Mathew; Priyanka Vijay; Ken Eng; Siraj Ali; Amy Johnson; Betty Chang; Scott Ely; Olivier Elemento; Christopher E Mason; John P Leonard; Selina Chen-Kiang
Journal:  Cancer Discov       Date:  2014-07-31       Impact factor: 39.397

8.  The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.

Authors:  Barbara Meissner; Robert Kridel; Raymond S Lim; Sanja Rogic; Kane Tse; David W Scott; Richard Moore; Andy J Mungall; Marco A Marra; Joseph M Connors; Christian Steidl; Randy D Gascoyne
Journal:  Blood       Date:  2013-02-13       Impact factor: 22.113

9.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.

Authors:  Timothy C Greiner; Chiranjib Dasgupta; Vincent V Ho; Dennis D Weisenburger; Lynette M Smith; James C Lynch; Julie M Vose; Kai Fu; James O Armitage; Rita M Braziel; Elias Campo; Jan Delabie; Randy D Gascoyne; Elaine S Jaffe; Hans K Muller-Hermelink; German Ott; Andreas Rosenwald; Louis M Staudt; Michael Y Im; Mazen W Karaman; Brian L Pike; Wing C Chan; Joseph G Hacia
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Authors:  Sílvia Beà; Rafael Valdés-Mas; Alba Navarro; Itziar Salaverria; David Martín-Garcia; Pedro Jares; Eva Giné; Magda Pinyol; Cristina Royo; Ferran Nadeu; Laura Conde; Manel Juan; Guillem Clot; Pedro Vizán; Luciano Di Croce; Diana A Puente; Mónica López-Guerra; Alexandra Moros; Gael Roue; Marta Aymerich; Neus Villamor; Lluís Colomo; Antonio Martínez; Alexandra Valera; José I Martín-Subero; Virginia Amador; Luis Hernández; Maria Rozman; Anna Enjuanes; Pilar Forcada; Ana Muntañola; Elena M Hartmann; María J Calasanz; Andreas Rosenwald; German Ott; Jesús M Hernández-Rivas; Wolfram Klapper; Reiner Siebert; Adrian Wiestner; Wyndham H Wilson; Dolors Colomer; Armando López-Guillermo; Carlos López-Otín; Xose S Puente; Elías Campo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205
  10 in total
  2 in total

1.  PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Authors:  Lindsay M Webb; Stephanie A Amici; Kyle A Jablonski; Himanshu Savardekar; Amanda R Panfil; Linsen Li; Wei Zhou; Kevin Peine; Vrajesh Karkhanis; Eric M Bachelder; Kristy M Ainslie; Patrick L Green; Chenglong Li; Robert A Baiocchi; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

2.  Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.

Authors:  Xiaoxian Zhao; Juraj Bodo; Ruoying Chen; Lisa Durkin; Andrew J Souers; Darren C Phillips; Eric D Hsi
Journal:  EJHaem       Date:  2020-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.